

Long-term Follow-up of MRC Myeloma IX Trial: Survival and Thalidomide Treatment

Clinical Cancer Research

19, 6030-6038

DOI: [10.1158/1078-0432.ccr-12-3211](https://doi.org/10.1158/1078-0432.ccr-12-3211)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Multiple myeloma: optimal management and long-term disease control. Blood and Lymphatic Cancer: Targets and Therapy, 2014, , 121.	1.2	0
2	Best Treatment Strategies in High-Risk Multiple Myeloma: Navigating a Gray Area. Journal of Clinical Oncology, 2014, 32, 2125-2132.	0.8	22
3	Immunological Dysregulation in Multiple Myeloma Microenvironment. BioMed Research International, 2014, 2014, 1-10.	0.9	106
4	Multiple Myeloma. Hematology/Oncology Clinics of North America, 2014, 28, 1113-1129.	0.9	4
5	United Kingdom Myeloma Forum position statement on the use of consolidation and maintenance treatment in myeloma. International Journal of Laboratory Hematology, 2014, 36, 665-675.	0.7	1
6	The emerging role of consolidation and maintenance therapy for transplant-eligible multiple myeloma patients. Expert Review of Hematology, 2014, 7, 55-66.	1.0	17
8	European Perspective on Multiple Myeloma Treatment Strategies in 2014. Oncologist, 2014, 19, 829-844.	1.9	90
9	Maintenance Therapy for Multiple Myeloma. Hematology/Oncology Clinics of North America, 2014, 28, 839-859.	0.9	14
10	The ecology of cancer from an evolutionary game theory perspective. Interface Focus, 2014, 4, 20140019.	1.5	68
11	Back to the Future! The Evolving Role of Maintenance Therapy after Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2014, 20, 154-163.	2.0	36
13	Reprint of: Back to the Future! The Evolving Role of Maintenance Therapy after Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2014, 20, S8-S17.	2.0	3
14	The evolving field of post-transplant therapy in multiple myeloma. Clinical Investigation, 2014, 4, 825-838.	0.0	0
15	Partial remission of acute myeloid leukemia complicating multiple myeloma following COAP chemotherapy: A case report. Oncology Letters, 2015, 9, 1303-1306.	0.8	1
16	Prediction of high- and low-risk multiple myeloma based on gene expression and the International Staging System. Blood, 2015, 126, 1996-2004.	0.6	106
17	Coexistent hyperdiploidy does not abrogate poor prognosis in myeloma with adverse cytogenetics and may precede IGH translocations. Blood, 2015, 125, 831-840.	0.6	57
18	Minimal residual disease in myeloma by flow cytometry: independent prediction of survival benefit per log reduction. Blood, 2015, 125, 1932-1935.	0.6	163
21	Consolidation and maintenance therapy for multiple myeloma after autologous transplantation: where do we stand?. Bone Marrow Transplantation, 2015, 50, 1024-1029.	1.3	31
22	Treatment of patients with multiple myeloma who are not eligible for stem cell transplantation: position statement of the myeloma foundation of <sc>A</sc>ustralia <sc>M</sc>edical and <sc>S</sc>cientific <sc>A</sc>dvisory <sc>G</sc>roup. Internal Medicine Journal, 2015, 45, 335-343.	0.5	6

#	ARTICLE	IF	CITATIONS
23	Relationship between Treatment Effects on Progression-Free Survival and Overall Survival in Multiple Myeloma: A Systematic Review and Meta-Analysis of Published Clinical Trial Data. <i>Oncology Research and Treatment</i> , 2015, 38, 88-94.	0.8	28
24	Current therapeutic strategies for multiple myeloma. <i>International Journal of Clinical Oncology</i> , 2015, 20, 423-430.	1.0	22
25	Bone antiresorptive agents in the treatment of bone metastases associated with solid tumours or multiple myeloma. <i>BoneKEy Reports</i> , 2015, 4, 744.	2.7	15
26	Role of stem cell transplant and maintenance therapy in plasma cell disorders. <i>Hematology American Society of Hematology Education Program</i> , 2016, 2016, 504-511.	0.9	2
27	Maintenance Therapy in Multiple Myeloma: Novel Concepts in Clinical Practice from Recent Clinical Trials. <i>Reviews on Recent Clinical Trials</i> , 2016, 11, 124-127.	0.4	0
28	Optimal treatment strategies in myeloma: An argument against maintenance therapy after autologous stem cell transplantation. <i>Seminars in Oncology</i> , 2016, 43, 714-717.	0.8	1
30	Role of stem cell transplant and maintenance therapy in plasma cell disorders. <i>Hematology American Society of Hematology Education Program</i> , 2016, 2016, 504-511.	0.9	22
31	Bone metastasis: the importance of the neighbourhood. <i>Nature Reviews Cancer</i> , 2016, 16, 373-386.	12.8	369
32	Minimal residual disease following autologous stem cell transplant in myeloma: impact on outcome is independent of induction regimen. <i>Haematologica</i> , 2016, 101, e69-e71.	1.7	41
33	Melphalan, prednisone, and lenalidomide versus melphalan, prednisone, and thalidomide in untreated multiple myeloma. <i>Blood</i> , 2016, 127, 1109-1116.	0.6	102
34	Plasma Cell Dyscrasias. <i>Cancer Treatment and Research</i> , 2016, , .	0.2	3
35	Treatment of Newly Diagnosed Elderly Multiple Myeloma. <i>Cancer Treatment and Research</i> , 2016, 169, 123-143.	0.2	9
36	Management of Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma. <i>Cancer Treatment and Research</i> , 2016, 169, 145-167.	0.2	7
37	Genome-wide association study identifies multiple susceptibility loci for multiple myeloma. <i>Nature Communications</i> , 2016, 7, 12050.	5.8	146
38	Oral ixazomib maintenance therapy in multiple myeloma. <i>Expert Review of Anticancer Therapy</i> , 2016, 16, 21-32.	1.1	6
39	Maintenance Therapy With Immunomodulatory Drugs in Multiple Myeloma: A Meta-Analysis and Systematic Review. <i>Journal of the National Cancer Institute</i> , 2016, 108, .	3.0	49
40	Genome-wide association study identifies variation at 6q25.1 associated with survival in multiple myeloma. <i>Nature Communications</i> , 2016, 7, 10290.	5.8	31
41	Bisphosphonates for cancer treatment: Mechanisms of action and lessons from clinical trials. , 2016, 158, 24-40.		158

#	ARTICLE	IF	CITATIONS
42	Adipose, Bone, and Myeloma: Contributions from the Microenvironment. <i>Calcified Tissue International</i> , 2017, 100, 433-448.	1.5	45
43	Management of multiple myeloma in older adults: Gaining ground with geriatric assessment. <i>Journal of Geriatric Oncology</i> , 2017, 8, 1-7.	0.5	25
44	Guidelines for screening and management of late and long-term consequences of myeloma and its treatment. <i>British Journal of Haematology</i> , 2017, 176, 888-907.	1.2	44
45	Prise en charge des lésions osseuses du myélome multiple: quelles particularités? <i>Revue Du Rhumatisme Monographies</i> , 2017, 84, 197-204.	0.0	0
46	An Evidence-Based Approach to Myeloma Bone Disease. <i>Current Hematologic Malignancy Reports</i> , 2017, 12, 109-118.	1.2	12
47	Multiple myeloma. <i>British Journal of Hospital Medicine (London, England: 2005)</i> , 2017, 78, C21-C27.	0.2	13
48	Prolonged Use of Zoledronic Acid (4 Years) Did Not Improve Outcome in Multiple Myeloma Patients. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, 207-210.	0.2	9
49	Zoledronic Acid Dosing Interval for Metastatic Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2017, 317, 1477.	3.8	0
50	Multiple Myeloma, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2017, 15, 230-269.	2.3	166
51	Overexpression of EZH2 in multiple myeloma is associated with poor prognosis and dysregulation of cell cycle control. <i>Blood Cancer Journal</i> , 2017, 7, e549-e549.	2.8	81
52	Osteonecrosis of the jaw and survival of patients with cancer: a nationwide cohort study in Denmark. <i>Cancer Medicine</i> , 2017, 6, 2271-2277.	1.3	17
53	Differential Depth Sensing Reduces Cancer Cell Proliferation <i>via</i> Rho-Rac-Regulated Invadopodia. <i>ACS Nano</i> , 2017, 11, 7336-7348.	7.3	11
54	Outcomes of Maintenance Therapy with Bortezomib after Autologous Stem Cell Transplantation for Patients with Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 262-268.	2.0	33
55	Bisphosphonates in multiple myeloma: an updated network meta-analysis. <i>The Cochrane Library</i> , 2017, 2017, CD003188.	1.5	72
56	Autologous hematopoietic cell transplants for plasma cell myeloma: One, two, or none?. , 0, , 445-457.		0
57	Fixed duration vs continuous therapy in multiple myeloma. <i>Hematology American Society of Hematology Education Program</i> , 2017, 2017, 212-222.	0.9	24
59	Possible targets to treat myeloma-related osteoclastogenesis. <i>Expert Review of Hematology</i> , 2018, 11, 325-336.	1.0	9
60	Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, double-blind, double-dummy, randomised, controlled, phase 3 study. <i>Lancet Oncology</i> , 2018, 19, 370-381.	5.1	300

#	ARTICLE	IF	CITATIONS
61	Carfilzomib for relapsed or refractory multiple myeloma – Authors' reply. <i>Lancet Oncology</i> , The, 2018, 19, e2.	5.1	2
62	Carfilzomib for relapsed or refractory multiple myeloma. <i>Lancet Oncology</i> , The, 2018, 19, e1.	5.1	1
63	Newly Diagnosed Multiple Myeloma in Transplant-Eligible Patients. , 2018, , 551-571.		0
64	A population-based study of the impact of dialysis on mortality in multiple myeloma. <i>British Journal of Haematology</i> , 2018, 180, 588-591.	1.2	20
65	Prediction of outcome in newly diagnosed myeloma: a meta-analysis of the molecular profiles of 1905 trial patients. <i>Leukemia</i> , 2018, 32, 102-110.	3.3	177
66	Outcomes of maintenance therapy with lenalidomide or bortezomib in multiple myeloma in the setting of early autologous stem cell transplantation. <i>Leukemia</i> , 2018, 32, 712-718.	3.3	27
67	New agents in the Treatment of Myeloma Bone Disease. <i>Calcified Tissue International</i> , 2018, 102, 196-209.	1.5	37
68	Post-Transplantation Management Strategies. , 0, , .		0
69	Thalidomide before and after autologous stem cell transplantation in recently diagnosed multiple myeloma (HOVON-50): long-term results from the phase 3, randomised controlled trial. <i>Lancet Haematology</i> , the, 2018, 5, e479-e492.	2.2	25
70	How I treat the young patient with multiple myeloma. <i>Blood</i> , 2018, 132, 1114-1124.	0.6	38
71	Quality of life during and following sequential treatment of previously untreated patients with multiple myeloma: findings of the Medical Research Council Myeloma <sc>IX</sc> randomised study. <i>British Journal of Haematology</i> , 2018, 182, 816-829.	1.2	23
72	Maintenance Treatment and Survival in Patients With Myeloma. <i>JAMA Oncology</i> , 2018, 4, 1389.	3.4	67
73	Methods to prevent and treat relapse after hematopoietic stem cell transplantation with tyrosine kinase inhibitors, immunomodulating drugs, deacetylase inhibitors, and hypomethylating agents. <i>Bone Marrow Transplantation</i> , 2019, 54, 497-507.	1.3	11
74	Role of the RANK/RANKL Pathway in Multiple Myeloma. <i>Clinical Cancer Research</i> , 2019, 25, 12-20.	3.2	48
75	The evolving role of maintenance therapy following autologous stem cell transplantation in multiple myeloma. <i>Expert Review of Anticancer Therapy</i> , 2019, 19, 889-898.	1.1	6
76	Use of bone-modifying agents and clinical outcomes in older adults with multiple myeloma. <i>Cancer Medicine</i> , 2019, 8, 6945-6954.	1.3	5
77	Monocytic Myeloid Derived Suppressor Cells in Hematological Malignancies. <i>International Journal of Molecular Sciences</i> , 2019, 20, 5459.	1.8	17
78	Ixazomib – Thalidomide – Dexamethasone for induction therapy followed by Ixazomib maintenance treatment in patients with relapsed/refractory multiple myeloma. <i>British Journal of Cancer</i> , 2019, 121, 751-757.	2.9	17

#	ARTICLE	IF	CITATIONS
79	Thalidomide maintenance therapy in Japanese myeloma patients: a multicenter, phase II clinical trial (COMET study). <i>International Journal of Hematology</i> , 2019, 109, 409-417.	0.7	3
80	Management of Newly Diagnosed Elderly Multiple Myeloma Patients. <i>Current Oncology Reports</i> , 2019, 21, 64.	1.8	16
81	A patent review of bisphosphonates in treating bone disease. <i>Expert Opinion on Therapeutic Patents</i> , 2019, 29, 315-325.	2.4	19
82	Clinical Trial Outcomes. <i>JACC: Heart Failure</i> , 2019, 7, 272-273.	1.9	6
83	Bisphosphonates. <i>Journal of Pain and Symptom Management</i> , 2019, 57, 1018-1030.	0.6	6
84	A clinical prediction model for outcome and therapy delivery in transplant-ineligible patients with myeloma (UK Myeloma Research Alliance Risk Profile): a development and validation study. <i>Lancet Haematology</i> , 2019, 6, e154-e166.	2.2	71
85	Physicians, paraproteins and progress: diagnosis and management of myeloma. <i>British Journal of Hospital Medicine (London, England: 2005)</i> , 2019, 80, 91-98.	0.2	6
86	Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial. <i>Lancet Oncology</i> , 2019, 20, 57-73.	5.1	245
87	Metastatic bone disease: Pathogenesis and therapeutic options. <i>Journal of Bone Oncology</i> , 2019, 15, 100205.	1.0	153
88	Efficacy of first-line treatments for multiple myeloma patients not eligible for stem cell transplantation: a network meta-analysis. <i>Haematologica</i> , 2019, 104, 1026-1035.	1.7	17
89	Bone metastases. <i>Nature Reviews Disease Primers</i> , 2020, 6, 83.	18.1	246
90	Bone health in cancer: ESMO Clinical Practice Guidelines. <i>Annals of Oncology</i> , 2020, 31, 1650-1663.	0.6	242
91	Lenalidomide before and after ASCT for transplant-eligible patients of all ages in the randomized, phase III, Myeloma XI trial. <i>Haematologica</i> , 2020, 106, haematol.2020.247130.	1.7	16
92	Predicting ultrahigh risk multiple myeloma by molecular profiling: an analysis of newly diagnosed transplant eligible myeloma XI trial patients. <i>Leukemia</i> , 2020, 34, 3091-3096.	3.3	26
93	Developments in continuous therapy and maintenance treatment approaches for patients with newly diagnosed multiple myeloma. <i>Blood Cancer Journal</i> , 2020, 10, 17.	2.8	75
94	Optimising the value of immunomodulatory drugs during induction and maintenance in transplant ineligible patients with newly diagnosed multiple myeloma: results from Myeloma XI, a multicentre, open-label, randomised, Phase III trial. <i>British Journal of Haematology</i> , 2021, 192, 853-868.	1.2	14
95	Clodronate. <i>Bone</i> , 2021, 143, 115715.	1.4	13
96	Phase II trial of single-agent panobinostat consolidation improves responses after suboptimal transplant outcomes in multiple myeloma. <i>British Journal of Haematology</i> , 2021, 193, 160-170.	1.2	4

#	ARTICLE	IF	CITATIONS
97	Efficacy of proteasome inhibitor-based maintenance following autologous transplantation in multiple myeloma: A systematic review and meta-analysis. <i>European Journal of Haematology</i> , 2021, 106, 40-48.	1.1	2
98	Bone Targeted Therapies. Resistance To Targeted Anti-cancer Therapeutics, 2021, , 105-127.	0.1	0
99	Role of Stem Cell Transplantation in Multiple Myeloma. <i>Cancers</i> , 2021, 13, 863.	1.7	17
101	Prevalence and Survival Impact of Self-Reported Symptom and Psychological Distress Among Patients With Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, e284-e289.	0.2	9
102	Sex Differences in Multiple Myeloma Biology but not Clinical Outcomes: Results from 3894 Patients in the Myeloma XI Trial. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, 667-675.	0.2	12
103	Bone remineralization of lytic lesions in multiple myeloma – The Arkansas experience. <i>Bone</i> , 2021, 146, 115876.	1.4	4
104	Safety of lenalidomide for maintenance treatment of patients with multiple myeloma following autologous stem cell transplantation. <i>Expert Opinion on Drug Safety</i> , 2021, 20, 1137-1145.	1.0	2
105	The role of bone-modifying agents in myeloma bone disease. <i>JBMR Plus</i> , 2021, 5, e10518.	1.3	6
106	Knowing the unknowns in high risk multiple myeloma. <i>Blood Reviews</i> , 2022, 51, 100887.	2.8	6
107	The Roadmap of RANKL/RANK Pathway in Cancer. <i>Cells</i> , 2021, 10, 1978.	1.8	29
108	Rapid Progress in the Use of Immunomodulatory Drugs and Cereblon E3 Ligase Modulators in the Treatment of Multiple Myeloma. <i>Cancers</i> , 2021, 13, 4666.	1.7	10
109	Review of Myeloma Therapies and Their Potential for Oral and Maxillofacial Side Effects. <i>Cancers</i> , 2021, 13, 4479.	1.7	2
110	Thrombosis in patients with myeloma treated in the Myeloma IX and Myeloma XI phase 3 randomized controlled trials. <i>Blood</i> , 2020, 136, 1091-1104.	0.6	58
111	The varied distribution and impact of <i>RAS</i> codon and other key DNA alterations across the translocation cyclin D subgroups in multiple myeloma. <i>Oncotarget</i> , 2017, 8, 27854-27867.	0.8	25
112	Updated recommendations for diagnosis and treatment of plasma cell myeloma in Switzerland. <i>Swiss Medical Weekly</i> , 2019, 149, w20031.	0.8	4
113	Multiple Myeloma, Version 2.2016. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2015, 13, 1398-1435.	2.3	55
114	Multiple Myeloma, Version 3.2021, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2020, 18, 1685-1717.	2.3	138
115	Management of Adverse Events and Supportive Therapy in Relapsed/Refractory Multiple Myeloma. <i>Cancers</i> , 2021, 13, 4978.	1.7	6

#	ARTICLE	IF	CITATIONS
116	Treatment of elderly patients with myeloma. , 2015, , 41-63.		0
117	Therapiestrategien beim multiplen Myelom im Rezidiv oder Progress nach Prim�rtherapie. , 2016, , 135-143.		0
118	Multiples Myelom beim alten und geriatrischen Patienten. , 2018, , 1-10.		0
119	Risk Stratification in Newly Diagnosed Transplant Ineligible Multiple Myeloma. , 2018, , 37-58.		0
120	Multiples Myelom beim alten und geriatrischen Patienten. , 2018, , 261-270.		0
121	Endokrines System und Immunmodulation. , 2018, , 721-796.		0
123	Atypical femur fracture in a woman with osteogenesis imperfecta and multiple myeloma. Journal of Musculoskeletal Neuronal Interactions, 2018, 18, 375-381.	0.1	3
125	Patient-Reported Outcomes in Randomized Controlled Trials of Patients with Multiple Myeloma: A Systematic Literature Review of Studies Published Between 2014 and 2021. Clinical Lymphoma, Myeloma and Leukemia, 2022, 22, 442-459.	0.2	7
126	Endokrines System und Immunmodulation. , 2022, , 799-885.		0
127	The importance of retaining physical functions to prevent skeletal�related events in multiple myeloma patients with bone disease. EJHaem, 0, , .	0.4	1
128	Evolution or revolution in multiple myeloma therapy and the role of the UK. British Journal of Haematology, 2020, 191, 542-551.	1.2	3
130	The Osteoclast Traces the Route to Bone Tumors and Metastases. Frontiers in Cell and Developmental Biology, 2022, 10, .	1.8	12
131	Fitnessexposed therapy in transplant ineligible patients with newly diagnosed Multiple Myeloma (FITNESS (UK-MRA Myeloma XIV Trial)): a study protocol for a randomised phase III trial. BMJ Open, 2022, 12, e056147.	0.8	11
132	The Nitrogen Mustards. Pharmacological Reviews, 2022, 74, 552-599.	7.1	13
133	Network meta-analysis of randomized trials in multiple myeloma: Efficacy and safety in frontline therapy for patients not eligible for transplant. Hematological Oncology, 2022, 40, 987-998.	0.8	5
134	The use of bone-modifying agents in multiple myeloma. Blood Reviews, 2023, 57, 100999.	2.8	2
135	Efficacy of maintenance treatment in patients with multiple myeloma: a systematic review and network meta-analysis. Hematology, 2022, 27, 1069-1088.	0.7	2
137	Time-to-event surrogate endpoints in multiple myeloma randomised trials from 2005 to 2019: A surrogacy analysis. British Journal of Haematology, 2023, 200, 587-594.	1.2	2

#	ARTICLE	IF	CITATIONS
138	Geranylgeranyl diphosphate synthase: Role in human health, disease and potential therapeutic target. <i>Clinical and Translational Medicine</i> , 2023, 13, .	1.7	9
139	AAOS Clinical Practice Guideline Summary: Treatment of Metastatic Carcinoma and Myeloma of the Femur. <i>Journal of the American Academy of Orthopaedic Surgeons</i> , The, 2023, 31, e118-e129.	1.1	4
140	Real world outcomes of lenalidomide or bortezomib maintenance in patients with multiple myeloma not undergoing stem cell transplantation. <i>Annals of Hematology</i> , 2023, 102, 1171-1184.	0.8	0
141	Lenalidomide or bortezomib as maintenance treatment remedy the inferior impact of high-risk cytogenetic abnormalities in non-transplant patients with newly diagnosed multiple myeloma: a real-world multi-centered study in China. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	0